Search clinical trials for: ALGRX 4975

Total 99 results

AlgoRx Pharmaceuticals

Completed

ALGRX 4975 in the Treatment of Patients With Morton's Neuroma

Neuroma

United States
AlgoRx Pharmaceuticals

Completed

ALGRX 4975 in the Treatment of Tennis Elbow

Tennis Elbow

Slovakia
AlgoRx Pharmaceuticals

Completed

Efficacy and Safety of ALGRX 4975 in the Treatment of Postoperative Pain After Gall Bladder Removal

Postoperative Pain

Former Serbia and Montenegro
AlgoRx Pharmaceuticals

Completed

Efficacy and Safety of ALGRX 4975 in Treatment of Postoperative Pain After Hernia Repair

Postoperative Pain

Denmark
AlgoRx Pharmaceuticals

Completed

ALGRX 4975 After Total Knee Replacement

Knee Injuries | Arthroplasty, Replacement, Knee

United States
Rigshospitalet, Denmark

Completed

Sensory Function After Wound Instillation of Capsaicin

Primary Hyperalgesia

Denmark
AlgoRx Pharmaceuticals

Completed

Efficacy and Safety of ALGRX 3268 in Management of Needlestick Pain in Children.

Procedural Pain

United States
AlgoRx Pharmaceuticals

Completed

Efficacy and Safety of ALGRX 3268 in Children Undergoing Minor Needle-Stick Procedures.

Pain

United States
AlgoRx Pharmaceuticals

Completed

Study of ALGRX 3268 for Needlestick Pain in Children

Pain

United States
Centrexion Therapeutics

Completed

A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

Morton's Neuroma

United States
Centrexion Therapeutics

Completed

Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)

Osteoarthritis of the Knee

United States
Anesiva, Inc.

Completed

Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement

Total Knee Arthroplasty (Replacement)

United States
Centrexion Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

Painful Intermetatarsal Neuroma (Morton's Neuroma)

United States
Centrexion Therapeutics

Completed

A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain

Osteoarthritis, Knee

United States
Anesiva, Inc.

Completed

Efficacy and Safety Study of 4975 to Manage Pain of Bunionectomy

Pain

United States
Anesiva, Inc.

Terminated

Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement

Arthroplasty

United States
Centrexion Therapeutics

Completed

Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain

Osteoarthritis

United States
Centrexion Therapeutics

Completed

A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain

Osteoarthritis, Knee

United States
Senhwa Biosciences, Inc.

Active, not recruiting

Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

Carcinoma, Basal Cell

United States
Cylene Pharmaceuticals

Unknown

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Senhwa Biosciences, Inc.

Completed

A Study of Silmitasertib (CX-4945) in Healthy Subject

COVID-19

Taiwan
University of Arizona
Senhwa Biosciences, Inc.

Terminated

Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19) (CX4945)

Coronavirus

United States
Chong Kun Dang Pharmaceutical

Completed

The Clinical Trial to Evaluate the Efficacy and Safety of CKD-497

Respiratory Infection

Korea, Republic of
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI); American Lebanese Syrian Associated Charities...

Suspended

Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

Medulloblastoma, Childhood

United States
Bayer

Completed

Safety of Gadovist in Renally Impaired Patients (GRIP)

Fibrosis | Renal Impairment

Italy, Spain, Korea, Republic of, Germany, Canada, France, Austria, Thailand, Australia, Switzerland
Bayer

Completed

Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging

Magnetic Resonance Imaging

Japan
Bayer

Completed

Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients in Magnetic Resonance Imaging

Magnetic Resonance Imaging

Philippines
Bayer

Completed

Gadobutrol Enhanced MRA of the Supra-aortic Vessels (GEMSAV)

Carotid Stenosis

France, China, United States, Austria, Poland, Australia, Italy, Turkey, Germany, Korea, Republic of, Sweden, Switzerland, Czechia, Argentina
Bayer

Completed

GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients (GARDIAN)

Magnetic Resonance Imaging | Magnetic Resonance Angiography

Poland, China, France, Germany, Hungary, Korea, Republic of, South Africa, Spain, Thailand, Taiwan, Czech Republic, Hong Kong, Italy, Kazakhstan, Russian Federation, Bosnia and Herzegovina, Greece, Canada, Vietnam, Kyrgyzstan
Bayer

Completed

Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON)

Epidemiologic Factors

Germany
Cylene Pharmaceuticals

Unknown

Dose-escalation Study of Oral CX-4945

Breast Cancer | Multiple Myeloma | Advanced Solid Tumors | Inflammatory Breast Cancer | Castleman's Disease

United States
Gilead Sciences

Terminated

Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis (Falcon)

Ulcerative Colitis

United States, France, Australia, Italy, Poland, Germany, Austria, Canada, Switzerland
Bayer

Completed

Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

Magnetic Resonance Imaging

United States, Canada, Germany
Bayer

Completed

Gadobutrol Enhanced MRA of the Renal Arteries (GRAMS)

Renal Artery Obstruction

Taiwan, United States, Korea, Republic of, France, Turkey, Switzerland, Austria, Poland, Brazil, Colombia, Germany, Czech Republic, Argentina
Bayer

Completed

Myocardial Perfusion MRI

Magnetic Resonance Imaging | Myocardial Perfusion Imaging

Switzerland, Germany, Austria, Poland
Bayer

Completed

Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging

Central Nervous System Diseases

Korea, Republic of, United States, Colombia, China, Argentina
Bayer

Completed

Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) (GadaCAD 2)

Coronary Artery Disease

United States, Canada, Singapore, Australia
Bayer

Completed

Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) (GadaCAD 1)

Coronary Artery Disease

New Zealand, United Kingdom, United States, France, Germany, Korea, Republic of, Switzerland
Bayer

Completed

A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children

Magnetic Resonance Imaging

Sweden, Canada, Austria, Germany
Bayer

Completed

A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting

Contrast Enhancement in Magnetic Resonance Imaging

United States
Bayer

Completed

Drug Use Investigation of Gadovist.

Magnetic Resonance Imaging | Image Enhancement

Japan
Bayer

Completed

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI) (GEMMA 2)

Breast Cancer

Spain, Canada, Taiwan, United States, India, Netherlands, Poland, Germany, Argentina
Bayer

Completed

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI

Breast Cancer | Diagnostic Imaging

Italy, Korea, Republic of, Switzerland, Colombia, United States, Brazil, Germany, Finland, Argentina
Bayer

Completed

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

Brain Metastases

Japan
Bayer

Completed

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients

Central Nervous System Diseases

China
Bayer

Completed

Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.

Neoplastic CNS Lesions

Italy
Bayer

Completed

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Brain Diseases | Spinal Cord Diseases

United States, Colombia, Argentina, Brazil
Achaogen, Inc.

Terminated

A Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers

Healthy Volunteer

United States
National Institute of Allergy and Infectious Diseases...
Johns Hopkins Bloomberg School of Public Health

Completed

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults

Dengue

United States
Achaogen, Inc.
Defense Medical Research and Development Program

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers

Healthy Volunteer

United States

Search clinical trials for: ALGRX 4975

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations